Method for assessing ovarian aromatase activity |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for assessing ovarian aromatase activity (RU 2549491):
 Method for selecting trained workers maintaining railroad tunnel into risk group of incipient signs of health situations / 2546929
Method involves measuring total blood thyroxin, conducting spinal X-ray osteodensitometry and spirometry, and measuring mineral bone density at the lumbar level of L2-L3, and maximal expiratory flow at 25% and 50% of respiratory function. The obtained data are used to calculate F by formula F=25.1-0.14×a1-15.7×a2+0.42×a3-0.034×a4, wherein 25.1 is a constant; 0.14; 15.7; 0.42; 0.034 are discriminant coefficients; a1, 2,…, 4 are numerical values of the conducted examination; a1 is the total thyroxin concentration, nmol/l; a2 is a bone L2-L3 density coefficient; a3 is the maximal expiratory flow at 25% according to respiratory function, %; a4 is the maximal expiratory flow at 50% according to respiratory function, %. If F is equal to or more than the constant, the patient is stated to have no signs of health situations specific for this type of industry; if F is less than the constant, the patient is referred to a risk group of health situations.
Method for detecting synchronous tumour growth in male patients suffering colon cancer / 2546033
Invention refers to medicine, namely to a method for detecting the synchronous tumour growth in the male patients suffering colon cancer. Substance of the invention consists in measuring preoperative blood testosterone and intestinal cell-stimulating hormone by Immunotech test systems (Czech Republic) in the male patients suffering colon cancer. Testosterone/intestinal cell-stimulating hormone ratio is calculated; if the derived value falls within the range of 0.45-2.18 enables stating the presence of single colon cancer, while the values within the range of 0.03-0.38 provides stating the presence of synchronous tumours.
 Diagnostic technique for adolescent's reproductive disorders accompanying chronic renal pathology / 2536288
Technique involves a blood serum examination for thyrotropic hormone, mcUnit/ml, free T4, pmole/l, prolactine, mIU/ml, follicle-stimulating hormone, mIU/ml, lutenizing hormone, mIU/ml, testosterone, nmole/l, dehydroepiandrosterone sulphate, mcg/ml, cortisol, nmole/l, oestradiol, pg/ml, 17-OH progesterone, nmole/l. Calculating an integral hormone state (HIS) by formula follows. If the HIS value is below 0.799, a habitual disorder is stated, which is accompanied by a minimum risk of the reproductive disorders. The HIS values falling from the range of 0.800 to 1.000 provides stating the tensed hormonal regulation reflecting a moderate risk of the reproductive disorders. The disturbed interhormonal cooperation corresponds to the HIS value falling within the range of 1.001 to ≤1.210 that represents a high risk of the reproductive disorders. The HIS value of more than 1.211 shows the lack of reserves that testifies to a very high risk of the reproductive disorders.
Method of diagnostics of menstrual dysfunction against background of polycystic ovarian syndrome by immature girls / 2535096
For immature girls after day 3-5 of menstrual cycle a level of Anti-Mullerian Hormone is determined in blood serum by method of enzyme multiplied immunoassay (ELISA), and if its value exceeds 5.2 ng/ml the menstrual dysfunction is diagnosed against the background of polycystic ovarian syndrome.
Method for early prevention of gestational complications / 2530624
Method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%.
Diagnostic technique for renal functional reserve / 2528903
Invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.
Diagnostic technique for clinically latent hypercorticoidism in patients suffering from stype 2 diabetes mellitus or obesity / 2521387
First stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.
 Solid phase enzyme-immunoassay (eliza) for vascular endothelial growth factor (vegf) / 2517301
Invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.
Method for determining degree of severity of chronic obstructive pulmonary disease / 2516971
Blood is examined. The steroid hormones cortisol (nmole/l) and DHEA-S (mcmole/l), as well as the oxidative stress values - oxidative modified proteins (OMP, nM/mg, protein), malondialdehyde (MDA, nM/ml) and SH groups mg% are evaluated. The forced expiratory volume 1(%) FEV1 is calculated by formula on the basis of the derived values. If the derived FEV1 is within 50% to 80%, the presence of a moderate degree of chronic obstructive pulmonary disease; the FEV1 being within the range of 30 to 49% means a severe degree of chronic obstructive pulmonary disease (COPD), and the derived value being less than 30% shows an extremely severe degree of COPD.
Method for prediction of risk of early development of atherosclerosis in patients with chronic prostatitis / 2504782
Blood serum of the younger patient suffering chronic prostatitis is examined for total testosterone, sex hormone-binding globulin to calculate a free testosterone index; high-density lipoproteins and triacylglycerides are determined, and an atherogenic index is calculated by formula. If the atherogenic index is <3.7, a high risk of the early development of atherosclerosis is predicted.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: serum hormones are measured on the second day of the menstrual cycle prior to peroral administering letrozole aromatase inhibitor 10 mg and 48 hours after; pre-letrozole oestradiol and anti-Mullerian hormone and post-letrozole oestradiol are measured. An absolute decrease of post-letrozole oestradiol is determined, and an ovarian aromatase activity coefficient (K) is determined by formula. If K <9.1, the low ovarian aromatase activity is determined, the 9.1<K<27.3 shows the normal activity, while K>27.3 - the high activity. EFFECT: using the declared non-invasive method enables the high-accuracy assessment of the ovarian aromatase activity intensity. 5 tbl, 3 ex
The invention relates to medicine, namely to endocrinology of reproduction, and can be used to assess ovarian aromatase activity. Aromatase P450 - enzyme complex that catalyzes the conversion of C19-androgenic steroids into estrogen, realizing the biosynthesis of estrone from Androstenedione and estradiol (E2) from testosterone. In humans, aromatase P450 was detected in many tissues and organs such as the gonads, brain, adipose tissue, placenta, liver, skin, bones, blood vessels, endometrium, and in the endometrioid heterotopias in the tissue leiomyomas, endometrial cancer and breast cancer [Simpson E. R. Biology of aromatase in the mammary gland / E. R. Simpson [et al.] // J. Mammary Gland Biol. Neoplasia. - 2000. - Vol.5, N3. - P. 251-258]. In the ovaries of women in the reproductive period of aromatase found in the antral mucosa of dominant follicles and yellow bodies. The main activator aromatase activity is follicle-stimulating hormone (FSH), which depends, in turn, from the action of anti-Mullerian hormone (AMH). AMH is produced in the ovaries of women antral follicles and corresponds to their number [Fanchin R. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than seruminhibin B, estradiol, FSH and LH on day 3 / Fanchin R. [et al.] // Hum. Reprod. - 2003. - Vol.18, N2. - P. 323-327]. The gene for human aromatase is localized on the 15th chromosome. In the literature [Shozu M. A new cause of female pseudohermaphroditism: placental aromatase deficincy / M. Shozu [et al.] // J. Clin. Endocrinol. Metab. - 1991. - Vol.72, N3 - P. 560-566] find descriptions of patients with a defect P450 aromatase gene CYP19. The clinical picture of aromatase deficiency in patients of female gender is expressed intrauterine virilization of varying severity, hypergonadotropic hypogonadism, underdevelopment of secondary sexual characteristics, primary amenorrhea, infertility. Partial defect of the P450 aromatase gene CYP19 may be responsible for insufficient production of estradiol by the dominant follicle and play a role in the pathogenesis of anovulation and infertility. The known method of estimating the activity of aromatase by the ratio of the content of androgens and estrogens in the blood [E. V. Misharin Content of estrone, Androstenedione and β-endorphin in women with obesity and hormonal ovarian failure: author. dis. ... candidate. honey. Sciences. - SPb., 1993]. This method is appropriate for indirect estimation of total aromatase activity. Total aromataza activity can be measured by protein immunoblotting [L. Lin Variable phenotypes associated with aromatase (CYP19) insufficiency in humans / L. Lin [et al.] // J. Clin. Endocrinol. Metab. - 2007. - V. 92. P. 982-990]. In the process of determining aromatase activity uses the electrophoresis of blood proteins in polyacrylamide gel for the separation of denatured polypeptides in length or three-dimensional structure of native proteins. Next, the proteins are transferred to nitric�rulesnew membrane where aromatase is determined using specific antibodies. This method is distinguished by the complexity and the need for special equipment. In Oncology practice aromatase activity in various tissues is determined by radiometric method based on the conversion of tritiated Androstenedione in "heavy" water (3H-H2O) [Larionov A. A. Conversion of Androstenedione in tumor and extragonadal tissues and its relationship with hormonal and metabolic factors in patients with breast cancer: author. dis. ... candidate. honey. Sciences. - SPb., 1997]. The disadvantage of this method is its invasiveness. Known method of estimating aromatase activity in individual organs and tissues, including the ovaries women, immunohistochemical method [Suzuki T. Quantitation of P450 aromatase immunoreactivity in human ovary during the menstrual cycle: relationship between the enzyme activity and immunointensity / T. Suzuki [et al.] // J. Histochem. Cytochem. - 1994. - Vol.42, N12. - P. 1565-1573]. The method is based on the binding of unlabeled primary rabbit polyclonal antibodies with aromatase P450 with the formation of the immune complex. Further, the immune complex was visualized using a secondary labeled antibodies, the primary antibodies used for secondary antigens. Immunohistochemical analysis performed on paraffin sections. The tissue sections with a thickness of 5 μm, placed on glass slides, coated with a film of poly-L-l�Zina. Quantitative evaluation of the results of the immunohistochemical reactions were performed on photomicrographs obtained with fixation systems microscopic images, consisting of a microscope, digital camera, personal computer, software, AST-1, version 2.12 and Videotest-Morphology 5.0". Photography nuzzled at 400x magnification (10x eyepiece, 40x objective), with complete closure of the aperture diaphragm, raised contendere, in the Photo mode, the exposure time 1/20 s, the camera sensitivity is maximum, image size 1280×1024 pixels, graphic image format JPEG (normal). Determined aromataza activity in granulosa cells of follicles, using the integral indicator of the optical density and the number of granulosa cells in the subject. The disadvantage of this method is the need for invasive procedures, extraordinary complexity. Known method of estimating aromatase activity by conducting tests with letrozole [Savin V. A. Ovarian P450 aromatase in polycystic ovary syndrome / V. A. Savin [et al.] / / academic Medical journal.- 2012. - Vol. 11, ISS. 1. - 47-53]. Serum define the content of LH, FSH, E2, total testosterone and free testosterone levels before and after oral administration of 10 mg of inhibitor of aromatase letrozole and change of LH and FSH, as well as �of coefficientof E2/total testosterone and E2/free testosterone in 48 hours appreciate aromatase activity by using a point system. This method is adopted by the authors for the prototype. The disadvantage of this method is the extensive expensive hormonal tests. In the described method does not provide information about the source aromatase activity. Changes of gonadotropins in the blood are indirect indicators of reduction of E2 in the blood and depend on intactness or damage of negative feedback in the hypothalamic-pituitary-ovarian system. The technical result of the invention is to obtain accurate data about the level of ovarian aromatase activity. Said technical result is achieved in that in the method of assessing the ovarian aromatase activity by hormonal analysis of blood serum on the second day of the menstrual cycle prior to oral administration of 10 mg of inhibitor of aromatase letrozole and 48 hours after, according to the invention before the treatment with letrozole determine the level of estradiol and the level of anti-Mullerian hormone, after taking letrozole - estradiol levels, determine the absolute value of the change in estradiol and calculate the coefficient of ovarian aromatase activity according to the following formula: K=Δ2/AMH, where: Δ2 - the absolute value of the change in the level of estradiol after administration of letrozole, pmol/l; AMG - the level of anti-Mullerian hormone, ng/ml and appreciate ova�yalou aromatase activity, considering that when K<9,1 - low ovarian aromataza activity, when 9,1<K<27,3 - normal, when K>27,3 - high. Studies have shown that the proposed method reduced the level of E2 in the blood 48 hours after oral intake of 10 mg of letrozole allows to estimate the ovarian aromatase activity. This is proved by the results of the study are shown in table.1. As can be seen from table 1, in women with external genital endometriosis (EGE), confirmed at laparoscopy (n=30, mean age 29±0.4 years), after 3 months of application of the agonists Genotropin-releasing hormone, E2 reaction to the oral ingestion of 10 mg of letrozole is virtually nonexistent. Whereas in healthy women of reproductive age with preserved ovulatory cycle (n=15, mean age 27±0.4 years), confirmed by an ultrasound examination of the pelvic organs and the level of progesterone in the blood on day 20-21 of the menstrual cycle, under the influence of oral administration of 10 mg of letrozole on day 2 of the menstrual cycle is significant (p<0.05) reduction in E2 in the blood by 42.6±7.9 pmol/l (tab.1).
Since ovarian aromataza activity depends not only on the amount of the enzyme aromatase, but also on the number of antral follicles, for a more accurate picture of ovarian aromatase activity used the K factor (the ratio of ovarian aromatase activity) showing the ratio of the absolute values of changes in the level of E2 in the blood in response to receiving 10 mg of the aromatase inhibitor of letrozole to the AMH level, reflecting the number of antral follicles in the ovaries of women. The coefficient K was calculated from 15 healthy women of reproductive age (mean age was 27±0.4 years) with preserved ovulatory cycle, ACK�regenum ultrasound of the pelvic organs and the level of progesterone in the blood on day 20-21 of the menstrual cycle. The average value of ovarian aromatase activity (M±M) and confidence limits (p=0.05) in healthy women (n=15) are presented in table.2.
Thus, about low ovarian aromatase activity is judged when the percentage factor To less than 9,1, normal ovarian aromatase activity when the ratio To between 9.1 to 27.3, high ovarian aromatase activity is judged if the value To more than 27.3. The method is as follows. At 9 a.m. on the 2nd day of the menstrual cycle from the cubital vein of the patient to take 10 ml of blood for hormonal studies. Then the patient takes 10 mg of the aromatase inhibitor of letrozole per os. After 48 hours, a second blood sample was drawn. The ELISA method in the first portion of the blood to determine the levels of AMH and E2, while the second has only the level E2. About ovarian aromatase activity is judged by the coefficient K=Δ2/AMG, with its subsequent evaluation: if K<9,1 - low ovarian aromataza the activity of�, when 9,1<K<27,3 - normal, when K>27,3 - high. The inventive method is illustrated by the following clinical examples. Example 1. Patient L. T. S. 25 years with chronic ofnormogonadotropic anovulation and infertility. A study on the proposed method. In table.3 shows a reaction to letrozole, the level of AMH in the blood and value To patient L. T. S.
In response to the reception of letrozole in this patient there was a decrease in the level of E2 in the blood with 116,5 pmol/l to 91,9 pmol/l, the absolute value of reducing E2 amounted to 24.6 pmol/l, K=1,24, which indicates low ovarian aromatase active�there. Final diagnosis: partial aromatase deficiency, ofnormogonadotropic anovulation, primary infertility. Example 2. Patient A. V. S., 27 years old, with non-classical form of congenital hyperplasia of the adrenal cortex, ofnormogonadotropic ovarian failure, anovulation, optimizarea, hirsutism I. a study of the proposed method. In table.4 presents the results of research: reaction to letrozole, the level of AMH in the blood and the value To the patient A. B. C.
On the 3rd day of the sample in this patient there was a decrease in the content of E2 in the blood from 121.4 pmol/l to 103.7 pmol/l, abso�cozy decrease in E2 was equal to 17.7 pmol/l, K=9,8. Thus, ovarian aromataza activity does not extend beyond the normal fluctuations. It is not possible to link the development of ofnormogonadotropic anovulation in this patient with aromatase deficiency. Example 3. Patient A. I. N., 27 years old, with polycystic ovary syndrome, ofnormogonadotropic narkopolitsejskie ovarian failure, anovulation and infertility. A study on the proposed method. In table.5 presents the results of research: reaction to letrozole, the level of AMH in the blood and value To patient A. I. N.
In response to the reception of letrozole in the d�the auditors of the patient there was a decrease in the level of E2 in the blood with 206,2 pmol/l to 100.3 pmol/l, the absolute decrease in E2 is equal 105,9 pmol/l, K=54,0, indicating increased ovarian aromatase activity. The proposed method allows high accuracy (95%) to rate the intensity of ovarian aromatase activity by non-invasive, simple to perform and can be used in research practice, gynecological practice for the diagnosis of partial aromatase deficiency responsible for the violation of the synthesis of estradiol by the follicle and plays a role in the pathogenesis of anovulatory infertility. Diagnosis high ovarian aromatase activity may be essential for deciding on the medical application of aromatase inhibitors in oestrogen dependent diseases (endometriosis, uterine fibroids, cancer of the uterine body, cancer of the breast). Method of assessing the ovarian aromatase activity by hormonal analysis of blood serum on the second day of the menstrual cycle prior to oral administration of 10 mg of inhibitor of aromatase letrozole and 48 hours after, characterized in that before the treatment with letrozole determine the level of estradiol and the level of anti-Mullerian hormone, after taking letrozole - estradiol levels, determine the absolute value of the change in estradiol and calculate the coefficient of ovarian aromatase activity according to the following formulas�:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||